

Index

Note: Page numbers of articles titles are in **boldface** type.

A

- Anemia, preoperative, and hip fracture, 375, 376
- Anorexia, alterations in nutritional status in, 317
 - and cachexia therapy, functional assessment of (FAACT), 319
 - assessment of management of, 318–319, 320
 - chronic low-grade inflammation and, 317
 - cognitive impairment and, 318
 - depression and, 318
 - gastrointestinal muscular tone and, 316
 - medications review in, 317
 - nutritional counseling in, 316
 - of aging, **315–323**
 - treatment options for, 320–321
 - risk factors for, 317–318
 - social factors causing risk of malnutrition and, 318
 - taste and smell alterations and, 316
- Anorexia/nutrition care pathway, 320

B

- Brain, neurotoxic β -amyloid accumulation in, cognitive frailty and, 346

C

- Cachexia, muscle loss in, 309
- Cachexia therapy, anorexia and, functional assessment of (FAACT), 319
- Cardiac disorders, in depression, 388
- Cognition, and frailty, relationship between, 341
- Cognitive decline, age-related, 325
- Cognitive frailty, **339–355**
 - approach to, 340–341
 - cardiovascular risk factors for, 341–345
 - controversy concerning, 348–349
 - depression and, 347
 - hormonal changes involved in, 346
 - inflammation and, 346
 - lifestyle and mental health issues in, 347
 - mechanisms of, 341–347
 - neurotoxic β -amyloid accumulation in brain and, 346
 - nigral neuronal loss and, 346–347
 - nutrition as influence on, 345–346
 - prevention of, 348

Cognitive (*continued*)

- proposed definition of, 340
- tools to measure, 347–348

Cognitive function, and frailty, association between, 342–344

Cognitive impairment, and anorexia, 318

- and frailty, link between, history of, 340–341, 345

mild, **325–337**

- amnesic, 325
- characteristics of, 325, 326
- depression causing, 328
- early diagnosis of, 332
- epidemiology of, 326–327
- imaging studies and biomarkers in, 331–332
- in obstructive sleep apnea, 328
- lifestyle modifications in, 333
- metabolic deficiencies causing, 328
- nonamnesic, 325
- pathophysiology of, 327
- polypharmacy causing, 328
- progression to dementia, 332
- reversible causes of, 327–328
- risk factors for, 327
- screening and diagnosis in, 329
- screening instruments in, 329–331
- treatment of, 332–333

Cognitive screen, rapid, 434

D

Delirium, attention and, 397

- awareness of, future of, 408–409
- causes of, 398–399, 400
- cognitive changes in, neuropathophysiology hypotheses of, 399–400
- cognitive processes for, 396–398
- consciousness and, 396–397
- consequences of, 394, 396
- definition of, 394
- diagnosis of, and screening for, 396–398
- dissecting of, **393–413**
- ignored by health care, 396
- phenotypes of, 394
- phenotypic categorical models of, 395
- placebo-controlled intensive care unit studies in, 401, 403
- placebo-controlled trials in, 401, 402
 - randomized, 401, 404–405
- prevalence and incidence of, 394, 395
- prevention of, and treatment of, nonpharmacologic, 406–408
 - pharmacologic, 400–405
 - in people in institutional long-term care, 406–408

- multicomponent nonpharmacologic, 406, 407
- single component nonpharmacologic, 406
- with arousal, screening for, 398
- Delirium screening, “rapid,” 397–398, 399
- Dementia, end-of-life care and palliative care in, 422, 423
- progression of mild cognitive impairment to, 332
- DEMENTIAS mnemonic, 434
- Depression, and anorexia, 318
- and cognitive frailty, 347
- assessing of, challenges in, 385
- cardiac comorbidities in, 388
- causing mild cognitive impairment, 328
- diagnosis of, strategies to improve reliability of, 385
- endocrine disorders in, 388
- medical comorbidities in, 388, 389
- medication-induced, 387–388
- neurologic or psychiatric comorbidities in, 388–389
- screening for, in clinical encounter, 384–385
- in waiting room, 384
- with psychotic symptoms, 386–387
- Depression assessment, rapid, in geriatric patients, **383–391**
- Disability, and frailty, relationship between, 295

E

- End-of-life care, and palliative care, advantages of, 417
- and signs of dying process in, 420, 421
- dementia and, 422, 423
- determining life expectancy during, 420–422
- integrating of, in geriatric assessment, **415–429**
- prognostic indicators in, 420, 422
- prognostication in, 417–419
- quality of, challenges to, 427
- quality of death in, 417
- scope and definition of, 416, 420
- shared decision-making in, 416
- transition from curative care to, 419, 420
- clinical care in, 425–427
- Endocrine disorders, in depression, 388

F

- Falls, cognition and mood disorders and, 360
- comprehensive physical examination in, 363
- fracture risk assessment in, 362–363
- frailty, nutrition, oral health, 360
- home and environmental assessment in, 364
- in aging population, **357–368**
- in gait, balance, and neurologic impairment, 360–361
- in sensory impairment, 359

Falls (*continued*)

- laboratory and imaging investigations in, 364
- medications review and, 363
- nutrition, appetite, and sarcopenia assessment in, 362
- orthostatic hypotension and, 361
- prevalence, location, and consequences of, 358–359
- prevention of, interventions for, 364
- risk factors for, 359–361
- risk of, high, 362–364
 - low, 361
 - screening and assessment of, 361–364
- sedentary behavior and, 360
- Timed Up and Go Test (TUGT) and, 362

FRAIL acronym, 296–297

FRAIL screening test, 432

Frailty, and cognition, relationship between, 341

- and cognitive function, association between, 342–344
 - and cognitive impairment, link between, history of, 340–341, 345
 - and disability, relationship between, 295
 - assessment of, 295–297
 - cognitive. *See Cognitive frailty.*
 - concept of, in geriatric medicine literature, 294
 - definition of, 293, 294, 295
 - in older persons, **293–303**
 - management of, 297–299
 - natural course of, 300
 - specific issues in, 299–300
 - related to sarcopenia, 308–309
 - scientific publications on, 294
- Frailty Index, 296, 363
- Frailty phenotype, 295–296
- physical, 432–433

G

- Geriatric assessment, quality palliative and end-of-life care, integrating of, **415–429**
- rapid, **431–440**
 - advance directives and, 434

H

- Hip fracture, cognition assessment in, 370–371
- comorbidities and frailty in, 372–373
 - high-risk cardiac conditions and, 370
 - history taking in, 370
 - imaging in, 375, 376
 - medication review in, 373–374
 - mortality and morbidity due to, indicators of, 375–377
 - nutrition assessment in, 372
 - physical examination and pain assessment in, 371
 - preoperative anemia and, 375

- preoperative assessment in, 369–376, 377
- preoperative investigations and, 374–375
- rapid geriatric assessment of, **369–382**
- surgical risk in, 372
- timing of surgery in, 370
- vital signs assessment in, 371

Hormonal changes, and cognitive frailty, 346

I

Inflammation, and cognitive frailty, 346

- low-grade, anorexia and, 317

INTER-FRAIL instrument, 297

M

MEALS-ON-WHEELS, 433

Medications, inducing depression, 387–388

Medications review, and hip fracture, 373–374

- falls and, 363
- in anorexia, 317

Mental health issues, and cognitive frailty, 347

Mental Status Examination, Saint Louis University (SLUMS), 329–330, 388, 434

Muscle fiber structure, age-related changes in, 306

Muscle loss, in cachexia, 309

Muscle mass, and function, regulators of, 307

- loss of, 305
 - consequences of, 307–308

Muscle tone, anorexia and, 316

N

Neuronal loss, nigral, and cognitive frailty, 346–347

O

Obstructive sleep apnea, mild cognitive impairment in, 329

Orthostatic hypotension, falls and, 361

P

Palliative care, and end-of-life care. See *End-of-life care, and palliative care.*

Palliative clinical care, 423–425

Palliative Performance Scale, 422, 424

Parkinson disease patients, suicide in, 389

Polypharmacy, causing mild cognitive impairment, 328

Psychiatric impairments, in depression, 388–389

Psychosis, assessment of, 387

R

Rapid Geriatric Assessment, Saint Louis University (RGA), 431, 432
Resilience, definition of, 294–297

S

Saint Louis University, Mental Status Examination (SLUMS), 329–330, 388, 434
 Rapid Geriatric Assessment (RGA), 431, 432
SARC-F questionnaire, 433
Sarco-osteoporosis, 309
Sarcopenia, **305–314**
 definition(s) of, 306, 433
 compared, 306
 diagnosis of, 309, 310
 etiology of, 306–307
 frailty related to, 308–309
 modifiable causes of, 306–307
 nutritional recommendations in, 311
 prevalence of, 306
 syndromes and diseases closely related to, 308–309
 treatment of, biomarkers to monitor, 312
 nonpharmaceutical, 310–311
 pharmaceutical, 311–312
Sedentary behavior, falls and, 360
Sensory impairment, falls in, 359
Sherbrooke Postal Questionnaire, 6-item, 297
Simplified Nutritional Assessment Questionnaire (SNAQ), 319, 433
Suicidality, assessment of, 386
 risk factors for, 385–386
Suicide, in Parkinson disease patients, 389

T

Tilburg Frailty Indicator, 296
Timed Up and Go Test (TUGT), in falls, 362

V

Vitamin K antagonists, hip fracture and, 373